Organigram agrees C$561m Aurora deal, but Curaleaf's hostile bid has not yet lapsed

The Marijuana Herald reports that Organigram Global and Aurora Cannabis have agreed that Organigram will buy all Aurora shares for C$7.80 each, valuing the deal at about C$561 million (US$398 million). The report says the price is a 93% premium to Aurora's unaffected close on 10 August and 21% above the implied value of Curaleaf's competing offer as of 2 November.

Both boards approved the deal unanimously. Closing is expected in January 2027, subject to shareholder, regulatory and court approvals. Aurora holders may elect C$7.80 cash, 5.8626 Organigram shares, or C$3.75 plus 3.0431 shares, with proportional adjustments. British American Tobacco is to invest about C$187.5 million in a private placement, and ATB Financial has committed credit facilities of up to C$210 million. Special meetings are expected in December. Aurora needs at least two-thirds of votes cast, and Organigram shareholders must approve the share issue. Aurora holders would own about 35% of the combined economics and 42% of the votes.

What this means

The medical question is about sites and shipments, not heritage. The combined group says it would operate five EU-GMP certified facilities.

Recreational flower in a medical jar?

Germany's import chain does not look at a company's background. All imported medical cannabis must carry an EU-GMP certificate and meet European Pharmacopoeia monograph 3028, mandatory since 1 July 2024. Certificates are held by manufacturing sites, not companies, and each shipment needs a BfArM authorisation under § 12 MedCanG valid for at most three months. Canada keeps the channels apart by licence class. Health Canada's table says a sale-for-medical-purposes licence cannot be used to sell directly to provincial retailers. Neither the article nor our evidence says which five sites are certified or how Organigram will use them. The legal test is the certified site, not the brand.

Germany's reimbursement shift

Since 30 July 2026, § 31 Abs. 6 SGB V no longer covers cannabis flower. Statutory cover is limited to standardised extracts, dronabinol and nabilone medicines. Private flower prescriptions remain lawful, with the patient paying. A report by Newsweed says Aurora announced on 8 October 2026 an investment to more than double annual flower output at a German site. Organigram has also reported integrating Sanity Group. This suggests flower volumes will increasingly depend on self-pay demand, while extract and pharmacy-dronabinol lines stay reimbursable. Buyers and counterparties could test supply contracts against that split. A pending MedCanG amendment (printed paper 21/3061) would restrict mail-order, but it is not yet law.

Curaleaf

Curaleaf's offer is scheduled to expire on 4 December unless extended, amended or withdrawn, so it has not lapsed. Reports say the Alberta Securities Commission dismissed Curaleaf's challenge to Aurora's at-the-market programme. The December Aurora vote is the next test.

This is information, not legal, tax or financial advice.

Limits

• The article does not name the five EU-GMP sites or give Organigram's product plans for Aurora's medical lines.
• Regulatory approvals required are not specified, and the German import figure for 2025 (about 201 tonnes) rests on secondary reporting.
• News items are reports, not law.

Sources

• The Marijuana Herald, Organigram to Acquire Aurora Cannabis (3 November 2026)
• SGB V § 31
• BfArM, import and export
• Health Canada, import and export permits
• Health Canada, licence classes
• Newsweed, Aurora doubles German capacity
• Business Wire, Organigram Sanity update
• The Marijuana Herald, Alberta Securities Commission